Pages that link to "Q48311590"
Jump to navigation
Jump to search
The following pages link to Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas (Q48311590):
Displayed 43 items.
- MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma (Q21245768) (← links)
- Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference (Q21261312) (← links)
- O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients (Q24607903) (← links)
- Epigenetics of cervical cancer. An overview and therapeutic perspectives (Q24812104) (← links)
- Case comparison and literature review of glioblastoma: A tale of two tumors (Q27014996) (← links)
- Update on molecular findings, management and outcome in low-grade gliomas (Q30452178) (← links)
- Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. (Q33321068) (← links)
- The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide (Q33578787) (← links)
- First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response (Q33777877) (← links)
- O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer (Q34390612) (← links)
- Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). (Q34478948) (← links)
- MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. (Q34507966) (← links)
- Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma (Q35103214) (← links)
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment (Q35787908) (← links)
- MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR (Q35850389) (← links)
- Pathology and molecular genetics of astrocytic gliomas (Q35865773) (← links)
- Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas? (Q36037100) (← links)
- Low-grade gliomas: the debate continues (Q36432503) (← links)
- CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. (Q37261842) (← links)
- Epigenetic changes in gliomas (Q37287032) (← links)
- Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas (Q37409721) (← links)
- Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas (Q37580501) (← links)
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (Q37649471) (← links)
- MGMT promoter methylation in malignant gliomas (Q37781296) (← links)
- Targeted brain tumor treatment-current perspectives (Q37928916) (← links)
- Molecularly based management of gliomas in clinical practice (Q38551010) (← links)
- Up-front temozolomide in elderly patients with glioblastoma (Q43199595) (← links)
- Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas (Q45232729) (← links)
- O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? (Q46154959) (← links)
- Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas (Q46630773) (← links)
- Transcriptome-wide analysis reveals the progress of Cordyceps militaris subculture degeneration (Q47136636) (← links)
- MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities (Q48312103) (← links)
- MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors (Q48686096) (← links)
- CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. (Q48795538) (← links)
- IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival (Q49109048) (← links)
- Promoter methylation of RB1, P15, P16, and MGMT and their impact on the clinical course of pilocytic astrocytomas (Q49645086) (← links)
- IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. (Q50438788) (← links)
- Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene. (Q52150633) (← links)
- Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients. (Q54442349) (← links)
- A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas (Q57022593) (← links)
- Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study (Q89471305) (← links)
- Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis (Q91260356) (← links)
- Genotyping low-grade gliomas among Hispanics (Q92446617) (← links)